143 related articles for article (PubMed ID: 35547739)
1. FGFR2-BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model.
Lei JH; Zhang L; Wang Z; Peltier R; Xie Y; Chen G; Lin S; Miao K; Deng CX; Sun H
Front Immunol; 2022; 13():861221. PubMed ID: 35547739
[TBL] [Abstract][Full Text] [Related]
2. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
3. Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Lei JH; Lee MH; Miao K; Huang Z; Yao Z; Zhang A; Xu J; Zhao M; Huang Z; Zhang X; Chen S; Jiaying NG; Feng Y; Xing F; Chen P; Sun H; Chen Q; Xiang T; Chen L; Xu X; Deng CX
Adv Sci (Weinh); 2021 Nov; 8(21):e2100974. PubMed ID: 34514747
[TBL] [Abstract][Full Text] [Related]
4. JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Tian Y; Wang X; Zhao S; Liao X; Younis MR; Wang S; Zhang C; Lu G
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46626-46636. PubMed ID: 31751121
[TBL] [Abstract][Full Text] [Related]
5. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
6. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
[TBL] [Abstract][Full Text] [Related]
7. A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
Jiang Z; Cai G; Liu H; Liu L; Huang R; Nie X; Gui R; Li J; Ma J; Cao K; Luo Y
J Nanobiotechnology; 2024 May; 22(1):296. PubMed ID: 38811964
[TBL] [Abstract][Full Text] [Related]
8. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
[TBL] [Abstract][Full Text] [Related]
10. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
11. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional factor BRD4 promotes the stemness of esophageal cancer by activating the nuclear PD-L1/RelB axis.
Li S; Guo Q; Guo R; Xu H
Environ Toxicol; 2024 Feb; 39(2):669-679. PubMed ID: 37615218
[TBL] [Abstract][Full Text] [Related]
14. Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer.
Pascual-Reguant L; Serra-Camprubí Q; Datta D; Cianferoni D; Kourtis S; Gañez-Zapater A; Cannatá C; Espinar L; Querol J; García-López L; Musa-Afaneh S; Guirola M; Gkanogiannis A; Miró Canturri A; Guzman M; Rodríguez O; Herencia-Ropero A; Arribas J; Serra V; Serrano L; Tian TV; Peiró S; Sdelci S
EMBO Mol Med; 2023 Dec; 15(12):e18459. PubMed ID: 37937685
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
16. Histone H4 acetylation and the epigenetic reader Brd4 are critical regulators of pluripotency in embryonic stem cells.
Gonzales-Cope M; Sidoli S; Bhanu NV; Won KJ; Garcia BA
BMC Genomics; 2016 Feb; 17():95. PubMed ID: 26847871
[TBL] [Abstract][Full Text] [Related]
17. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
19. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]